Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations

Clinical Cancer Research

Volumn 3, Issue 3, 1997, Pages 449-454

  Georgiadis, Mark S ^b   Russell, Edward K ^a   Gazdar, Adi F ^a,c   Johnson, Bruce E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; LONG TERM CARE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; PRIORITY JOURNAL;

CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CELL CYCLE; CELL SURVIVAL; G2 PHASE; HUMANS; LUNG NEOPLASMS; MITOSIS; PACLITAXEL; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0030889417     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Rowinsky, E. K.,and Donehower, R. C. Drug therapy: paclitaxel (Taxol). N. Engl. J. Med.,332:1004-1014, 1995.
2. Liebmann, J.,Cook, J. A.,Lipschultz, C.,Teague, D.,Fisher, J.,and Mitchell, J. B. The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol®) in human tumor cell lines. Cancer Chemother. Pharmacol.,33:331-339, 1994.
3. Rowinsky, E. K.,Donehower, R. C.,Jones, R. J.,and Tucker, R. W. Microtubule changes and cytotoxicity in leukemic cell lines treated with Taxol. Cancer Res.,48:4093-4100, 1988.
4. Lopes, N. M.,Adams, E. G.,Pitts, T. W.,and Bhuyan, B. K. Cell kill kinetics and cell cycle effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother. Pharmacol.,32:235-242, 1993.
5. Liebmann, J. E.,Cook, J. A.,Lipschultz, C.,Teague, D.,Fisher, J.,and Mitchell, J. B. Cytotoxic studies of paclitaxel (Taxol®) in human tumour cell lines. Br. J. Cancer, 68:1104-1109, 1993.
6. Hainsworth, J. D.,Thompson, D. S.,and Greco, F. A. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. J. Clin. Oncol.,13:1609-1614, 1995.
7. Eisenhauer, E. A.,Huinink, W. W.,Swenerton, K. D.,Gianni, L. Myles, J.,f Burg, M. E.,Kerr, I, Vermerken, J. B.,Buser, K.,Colombo, N.,Bacon, M.,Santabarbara, P, Onetto, N.,Winograd, B.,and Canetta, R. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J. Clin. Oncol.,12:2654-2666, 1994.
8. Wiernik, P. H.,Schwanz, E. L.,Strauman, J. J.,Dutcher, J. P.,Lipton, R. B.,and Paietta, E. Phase I: clinical and pharmacokinetic study of Taxol. Cancer Res.,47:2486-2493, 1987.
9. Wilson, W. H.,Berg, S. L.,Bryant, G.,Wittes, R. E.,Bates, S.,Fojo, A.,Steinberg, S. M.,Goldspiel, B. R.,Herdt, J.,O'Shaughnessy, J.,Balis, F. M.,and Chabner, B. A. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J. Clin. Oncol.,12:1621-1629, 1994.
10. Spriggs, D. R.,and Tondini, C. Taxol administered as a 120 hour infusion. Invest. New Drugs, 10:275-278, 1992.
11. Arbuck, S. G.,Canetta, R.,Onetto, N.,and Christian, M. C. Current dosage and schedule issues in the development of paclitaxel (Taxol®). Semin. Oncol.,20:31-39, 1993.
12. Phelps, R. M.,Johnson, B. E.,Ihde, D. C.,Gazdar, A, F.,Carbone, D. P.,McClintock, P. R.,Linnoila, R. I.,Matthews, M. J.,Bunn, P. A.,Carney, D.,Minna, J. D.,and Mulshine, J. L. The NCI-Navy Medical Oncology Branch Cell Line Data Base. J. Cell. Biochem. Suppl.,24:32-91, 1996. [The entire data base is available on the American Type Culture Collection Web Site (WWW:http://www.atcc.org/).]
13. Carmichael, J.,Mitchell, J. B.,DeGraff, W. G.,Gamson, J.,Gazdar, A. F.,Johnson, B. E.,Glatstein, E.,and Minna, J. D. Chemosensitivity testing of human lung cancer cell lines using the MTT assay. Br. J. Cancer, 57:540-547, 1988.
14. Carmichael, J.,DeGraff, W. G.,Gazdar, A. F.,Minna, J. D.,and Mitchell, J. B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res.,47:936-942, 1987.
15. Lai, S. L.,Goldstein, L. J.,Gottesman, M. M.,Pastan, I.,Tsai, C. M.,Johnson, B. E.,Mulshine, J. L.,Ihde, D. C.,Kayser, K.,and Gazdar, A. F. MDR1 gene expression in lung cancer. J. Natl. Cancer Inst.,81: 1144-1150, 1989.
16. Lai, G. M.,Chen, Y. N.,Mickley, L. A.,Fojo, A. T.,and Bates, S. E. P-glycoprotein expression and schedule dependence of Adriamycin cytotoxicity in human colon carcinoma cell lines. Int. J. Cancer, 49:696-703, 1991.
17. Seidman, A. D.,Hochhauser, D.,Gollub, M.,Edelman, B. E.,Yao, T. J.,Hudis, C. A.,Francis, P.,Fenelly, D.,Gilewski, T. A.,Moynahan, M. E.,Currie, V.,Baselga, J.,Tong, W.,O'Donaghue, M.,Salvaggio, R.,Auguste, L.,Spriggs, D.,and Norton, L. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J. Clin. Oncol.,14:1877-1884, 1996.
18. Webster L.,Linsenmeyer, M.,Millward, M.,Morton, C.,Bishop, J.,and Woodcock, D. Measurement of Cremophor EL following Taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J. Natl. Cancer Inst.,85: 1685-1690, 1993.
19. Fjällskog, M. L.,Frii, L.,and Bergh, J. Paclitaxel-induced cytotoxicity - effects of Cremophor EL (castor oil) on two human breast cancer cell lines with acquired multidrug resistant phenotype and induced expression of the permeability glycoprotein. Eur. J. Cancer, 30A:687-690, 1994.
20. Liebmann J.,Cook, J. A.,and Mitchell, J. B. Cremophor EL, solvent for paclitaxel, and toxicity (Letter). Lancet, 342:8884, 1993.
21. Georgiadis, M. S.,Schuler, B. S.,Brown, J. E.,Kieffer, L. V.,Steinberg, S. M.,Wilson, W. H.,Takimoto, C. H.,Kelley, M. J.,and Johnson, B. E. Paclitaxel by 96-hour continuous infusion in combination with cisplatin: a phase I trial in patients with advanced lung cancer. J. Clin. Oncol.,15: 735-743, 1997.
22. Gianni, L.,Kearns, C. M.,Giani, A.,Capri, G.,Vigano, L.,Locatelli, A.,Bonadonna, G.,and Egorin, M. J. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/ pharmacodynamic relationships in humans. J. Clin. Oncol.,13:180-190, 1995.